- Home
- » Tags
- » Enzalutamide
Top View
- Fourth Quarter 2018 Update
- Investigator's Brochure Enzalutamide (MDV3100) Astellas Medivation, Inc
- CHMP Assessment Report
- Xtandi, INN-Enzalutamide
- Structure and Function of the Nuclear Receptor Superfamily and Current Targeted Therapies of Prostate Cancer
- XTANDI (Enzalutamide) 40 Mg Capsules Are Supplied As White to Off-White Oblong Soft Gelatin Capsules Imprinted in Black Ink with MDV
- Enzalutamide
- Most Common Medical Problems Are Listed Below
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Enzalutamide Inhibits Testosterone-Induced Growth Of
- Clinicaltrials.Gov Identifier: NCT02099864 Oregon Health & Science University OHSU Knight Cancer Institute OHSU Eirb Protocol #: 10241
- Human Blood-Based Exposure Levels of Persistent Organic Pollutant (POP
- (Nubeqa™), Apalutamide (Erleada™), Enzalutamide (Xtandi®), Abiraterone (Zytiga®, Yonsa®) EOCCO POLICY
- Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate In
- Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen
- Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
- Human Blood-Based Exposure Levels of Persistent Organic Pollutant (POP) T Mixtures Antagonise Androgen Receptor Transactivation and Translocation J
- Enzalutamide Therapy for Advanced Prostate Cancer: Efficacy, Resistance and Beyond
- Enzalutamide Drug Monograph
- PATIENT INFORMATION XTANDI® (Ex TAN Dee)
- Molecular Underpinnings of Enzalutamide Resistance
- Advanced Prostate Cancer Treatment
- Non-Coding Rnas Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance
- Appendix a - Product Name Index
- In the Treatment of Patients with Prostate Cancer
- A TITAN Step Forward: Apalutamide for Metastatic Castration- Sensitive Prostate Cancer
- CHMP Agenda of the 25-29 January 2021 Meeting
- Clinical and Immunologic Impact of Short-Course Enzalutamide Alone
- Therapeutic and Toxic Blood Concentrations of More Than 1100 Drugs and Other Xenobiotics
- Inhibition and Induction of CYP Enzymes in Humans: an Update
- XTANDI (Enzalutamide) 40 Mg Capsules Are Supplied As White to Off-White Oblong Soft Gelatin Capsules Imprinted in Black Ink with ENZ
- Escaping Enzalutamide: Malat1 Contributes to Resistance
- Enzalutamide in the Who Model List of Essential Medicines for the Treatment of Metastatic Castration Resistant Prostate Cancer
- Enzalutamide
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- 15Th Annual College Research Forum 2018
- Enzalutamide in Prostate Cancer, a Review on Enzalutamide and Cancer
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer Jinge Zhao1, Shu Ning1, Wei Lou1, Joy C
- Safety and Efficacy of Exercise Training in Men
- Analysis of Novel Enzalutamide-Resistant Cells: Upregulation of Testis-Specific Y-Encoded Protein Gene Promotes the Expression of Androgen Receptor Splicing Variant 7
- A Review of Prostate Cancer Treatment Impact on the CNS and Cognitive Function
- September 2021 California Advantage Large Group 4 Tier PPO Prescription Drug List
- Snapshot: Prostate Cancer Lamont J
- Apple Health "Medicaid" Preferred Drug List Effective January 1, 2020 the Apple Health Preferred Drug List (PDL) Has Products Listed in Groups by Drug Class
- Intravaginal DHEA
- Normal Öko-Institut